Johnson & Johnson fined $2.2 billion over kickbacks and other allegations
The revamped journal of Diagnostic and Statistical Manual of Mental Disorders is under fire for its authors’ ties to drug companies.
Johnson & Johnson has agreed to pay $2.2 billion to resolve allegations that it provided kickbacks to doctors and pharmacies to push three of its medicines, as well as promoted the drugs for uses not officially approved by the Food and Drug Administration.
The US Justice Department announced the settlement Monday. It is reportedly one of the largest health-care fraud settlements in US history.
"This global settlement resolves multiple investigations involving the antipsychotic drugs Risperdal and Invega — as well as the heart drug Natrecor and other Johnson & Johnson products," Attorney General Eric Holder said in a statement.
"The settlement also addresses allegations of conduct that recklessly put at risk the health of some of the most vulnerable members of our society — including young children, the elderly, and the disabled."
Under the terms of the settlement, Johnson & Johnson will pay $485 million in criminal fines and forfeiture, and make civil payments to federal and state governments amounting to $1.72 billion.
“When companies put profit over patients’ health and misuse taxpayer dollars, we demand accountability,” said Associate Attorney General Tony West.
“In addition to significant monetary sanctions, we will ensure that non-monetary measures are in place to facilitate change in corporate behavior and help ensure the playing field is level for all market participants.”